|
[1]AMARAPURKAR DN,HASHIMOTO E,LESMANA LA,et al.How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?[J].J Gastroenterol Hepatol,2007,22(6):788-793.
|
|
[2]TARGHER G,DAY CP,BONORA E.Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease[J].N Engl J Med,2010,363(14):1341-1350.
|
|
[3]BALDWIN W,MCRAE S,MAREK G,et al.Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome[J].Diabetes,2011,60(4):1258-1269.
|
|
[4]NAKAHARA T,HYOGO H,YONEDA M,et al.Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients[J].J Gastroenterol,2014,49(11):1477-1484.
|
|
[5]LI C,HSIEH MC,CHANG SJ.Metabolic syndrome,diabetes,and hyperuricemia[J].Curr Opin Rheumatol,2013,25(2):210-216.
|
|
[6]CHOI HK,FORD ES.Prevalence of the metabolic syndrome in individuals with hyperuricemia[J].Am J Med,2007,120(5):442-447.
|
|
[7]MANGGE H,ZELZER S,PUERSTNER P,et al.Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults[J].Obesity(Silver Spring),2013,21(1):e71-e77.
|
|
[8]EDWARDS NL.The role of hyperuricemia in vascular disorders[J].Curr Opin Rheumatol,2009,21(2):132-137.
|
|
[9]SHORT RA,JOHNSON RJ,TUTTLE KR.Uric acid,microalbuminuria and cardiovascular events in high-risk patients[J].Am J Nephrol,2005,25(1):36-44.
|
|
[10]TSOULI SG,LIBEROPOULOS EN,MIKHAILIDIS DP,et al.Elevated serum uric acid levels in metabolic syndrome:an active component or an innocent bystander?[J].Metabolism,2006,55(10):1293-1301.
|
|
[11]SHIH MH,LAZO M,LIU SH,et al.Association between serum uric acid and nonalcoholic fatty liver disease in the US population[J].J Formos Med Assoc,2015,114(4):314-320.
|
|
[12]XU CF,YU CH,XU L,et al.Hypouricemic therapy:a novel potential therapeutic option for nonalcoholic fatty liver disease[J].Hepatology,2010,52(5):1865-1866.
|
|
[13]LIANG J,PEI Y,GONG Y,et al.Serum uric acid and non-alcoholic fatty liver disease in non-hypertensive Chinese adults:the Cardiometabolic Risk in Chinese(CRC)study[J].Eur Rev Med Pharmacol Sci,2015,19(2):305-311.
|
|
[14]PEREZ-RUIZ F,ANIEL-QUIROGA MA,HERRERO-BEITES AM,et al.Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients[J].Rheumatol Int,2015,35(9):1519-1524.
|
|
[15]ESSAWY SS,ABDEL-SATER KA,ELBAZ AA.Comparing the effects of inorganic nitrate and allopurinol in renovascular complications of metabolic syndrome in rats:role of nitric oxide and uric acid[J].Arch Med Sci,2014,10(3):537-545.
|
|
[16]SZABO G,PETRASEK J.Inflammasome activation and function in liver disease[J].Nat Rev Gastroenterol Hepatol,2015,12(7):387-400.
|
|
[17]ZHANG X,ZHANG JH,CHEN XY,et al.Reactive oxygen speciesinduced TXNIP drives fructose-mediated hepatic inflammation and lipid accumulation through NLRP3 inflammasome activation[J].Antioxid Redox Signal,2015,22(10):848-870.
|
|
[18]SCHRODER K,ZHOU R,TSCHOPP J.The NLRP3 inflammasome:a sensor for metabolic danger?[J].Science,2010,327(5963):296-300.
|
|
[19]WANG W,WANG C,DING XQ,et al.Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats[J].Br J Pharmacol,2013,169(6):1352-1371.
|
|
[20]XU C,WAN X,XU L,et al.Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia:one stone hits two birds[J].J Hepatol,2015,62(6):1412-1419.
|
|
[21]NAKATSU Y,SENO Y,KUSHIYAMA A,et al.The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model[J].Am J Physiol Gastrointest Liver Physiol,2015,309(1):g42-g51.
|
|
[22]LONARDO A,LORIA P,LEONARDI F,et al.Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease.A case-control study[J].Dig Liver Dis,2002,34(3):204-211.
|
|
[23]SUN DQ,WU SJ,LIU WY,et al.Serum uric acid:a new therapeutic target for nonalcoholic fatty liver disease[J].Expert Opin Ther Targets,2016,20(3):375-387.
|
|
[24]YUAN H,YU C,LI X,et al.Serum uric acid levels and risk of metabolic syndrome:a dose-response Meta-analysis of prospective studies[J].J Clin Endocrinol Metab,2015,100(11):4198-4207.
|
|
[25]LIU Z,QUE S,ZHOU L,et al.Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence:a Meta-analysis of prospective studies[J].Sci Rep,2015,5:14325.
|
|
[26]LI Y,XU C,YU C,et al.Association of serum uric acid level with non-alcoholic fatty liver disease:a cross-sectional study[J].J Hepatol,2009,50(5):1029-1034.
|
|
[27]XU C,YU C,XU L,et al.High serum uric acid increases the risk for nonalcoholic fatty liver disease:a prospective observational study[J].PLo S One,2010,5(7):e11578.
|
|
[28]SIROTA JC,MCFANN K,TARGHER G,et al.Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States:liver ultrasound data from the National Health and Nutrition Examination Survey[J].Metabolism,2013,62(3):392-399.
|
|
[29]WU SJ,ZHU GQ,YE BZ,et al.Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults:a large population-based study[J].Medicine(Baltimore),2015,94(17):e802.
|
|
[30]SERTOGLU E,ERCIN CN,CELEBI G,et al.The relationship of serum uric acid with non-alcoholic fatty liver disease[J].Clin Biochem,2014,47(6):383-388.
|
|
[31]CARDOSO AS,GONZAGA NC,MEDEIROS CC,et al.Association of uric acid levels with components of metabolic syndrome and non-alcoholic fatty liver disease in overweight or obese children and adolescents[J].J Pediatr(Rio J),2013,89(4):412-418.
|
|
[32]SUNDY JS,BARAF HS,YOOD RA,et al.Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment:two randomized controlled trials[J].JAMA,2011,306(7):711-720.
|
DownLoad: